These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 15277696)
21. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
22. Genetic modification of dendritic cells and its application for cancer immunotherapy. Nishioka Y; Hua W; Nishimura N; Sone S J Med Invest; 2002 Feb; 49(1-2):7-17. PubMed ID: 11901764 [TBL] [Abstract][Full Text] [Related]
23. Dendritic cells as vectors for immunotherapy of tumor and its application for gastric cancer therapy. Wu Y; Wang L; Zhang Y Cell Mol Immunol; 2004 Oct; 1(5):351-6. PubMed ID: 16285894 [TBL] [Abstract][Full Text] [Related]
24. Interferon gamma stimulates cellular maturation of dendritic cell line DC2.4 leading to induction of efficient cytotoxic T cell responses and antitumor immunity. He T; Tang C; Xu S; Moyana T; Xiang J Cell Mol Immunol; 2007 Apr; 4(2):105-11. PubMed ID: 17484804 [TBL] [Abstract][Full Text] [Related]
25. DCs and CD40-activated B cells: current and future avenues to cellular cancer immunotherapy. Schultze JL; Grabbe S; von Bergwelt-Baildon MS Trends Immunol; 2004 Dec; 25(12):659-64. PubMed ID: 15530836 [TBL] [Abstract][Full Text] [Related]
27. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Suzuki T; Fukuhara T; Tanaka M; Nakamura A; Akiyama K; Sakakibara T; Koinuma D; Kikuchi T; Tazawa R; Maemondo M; Hagiwara K; Saijo Y; Nukiwa T Clin Cancer Res; 2005 Jan; 11(1):58-66. PubMed ID: 15671528 [TBL] [Abstract][Full Text] [Related]
28. Cancer vaccines for established cancer: how to make them better? Andrews DM; Maraskovsky E; Smyth MJ Immunol Rev; 2008 Apr; 222():242-55. PubMed ID: 18364006 [TBL] [Abstract][Full Text] [Related]
29. Dendritic cells and their role in cancer immunotherapy. Jalili A Iran J Immunol; 2007 Sep; 4(3):127-44. PubMed ID: 17767012 [TBL] [Abstract][Full Text] [Related]
30. Dendritic cell vaccination for cancer therapy. Nestle FO Oncogene; 2000 Dec; 19(56):6673-9. PubMed ID: 11426654 [TBL] [Abstract][Full Text] [Related]
31. The use of dendritic cells in cancer immunotherapy. Nencioni A; Grünebach F; Schmidt SM; Müller MR; Boy D; Patrone F; Ballestrero A; Brossart P Crit Rev Oncol Hematol; 2008 Mar; 65(3):191-9. PubMed ID: 18055210 [TBL] [Abstract][Full Text] [Related]
32. Advances in specific immunotherapy for prostate cancer. Kiessling A; Füssel S; Wehner R; Bachmann M; Wirth MP; Rieber EP; Schmitz M Eur Urol; 2008 Apr; 53(4):694-708. PubMed ID: 18061335 [TBL] [Abstract][Full Text] [Related]
33. Current issues in delivering DCs for immunotherapy. Barratt-Boyes SM; Figdor CG Cytotherapy; 2004; 6(2):105-10. PubMed ID: 15203986 [TBL] [Abstract][Full Text] [Related]
34. DC-based cancer vaccines. Gilboa E J Clin Invest; 2007 May; 117(5):1195-203. PubMed ID: 17476349 [TBL] [Abstract][Full Text] [Related]
35. Dendritic cell-tumor cell hybrids enhance the induction of cytotoxic T lymphocytes against murine colon cancer: a comparative analysis of antigen loading methods for the vaccination of immunotherapeutic dendritic cells. Yasuda T; Kamigaki T; Nakamura T; Imanishi T; Hayashi S; Kawasaki K; Takase S; Ajiki T; Kuroda Y Oncol Rep; 2006 Dec; 16(6):1317-24. PubMed ID: 17089056 [TBL] [Abstract][Full Text] [Related]
36. Dendritic cells as natural adjuvants. Citterio S; Rescigno M; Foti M; Granucci F; Aggujaro D; Gasperi C; Matyszak MK; Girolomoni G; Ricciardi-Castagnoli P Methods; 1999 Sep; 19(1):142-7. PubMed ID: 10525450 [TBL] [Abstract][Full Text] [Related]
37. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies. Klippstein R; Pozo D Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824 [TBL] [Abstract][Full Text] [Related]
39. Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. Weigel BJ; Panoskaltsis-Mortari A; Diers M; Garcia M; Lees C; Krieg AM; Chen W; Blazar BR Exp Hematol; 2006 Oct; 34(10):1403-12. PubMed ID: 16982333 [TBL] [Abstract][Full Text] [Related]